


Due Date: April 6, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Joo Young Chung et al. Examiner: L. Spector
Serial No.: 09/720,410 Group Art Unit: 1647
Filed: December 21, 2000 Docket: G&C 118.7-US-WO
Title: A NOVEL HUMAN THROMBOPOIETIN MUTEIN

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence is being filed via facsimile transmission to the U.S. Patent and Trademark Office on April 8, 2002.

By: 
Name: Karen S. Canady

AMENDMENT UNDER 37 C.F.R. §1.111 AND
RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated February 6, 2002, please amend the above-identified application as follows. Please note that, in compliance with the new rules under 37 C.F.R. § 1.121, the amended claims are presented in "clean" form with marked-up versions provided in Appendix A.

IN THE CLAIMS

Please amend claim 1 as follows:

- B¹
1. (TWICE AMENDED) A human thrombopoietin derivative which is derived from human thrombopoietin (hTPO) described by SEQ ID NO: 30; which elicits approximately equal or greater biological activity as compared to native hTPO; which has at least one additional N-linked glycosylation site; and which is selected from the group consisting of:
[Asn¹⁰⁸] hTPO;